A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older

NCT06551181 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2621

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus Infections

Interventions

BIOLOGICAL: RSVPreF3 OA investigational vaccine
DRUG: Placebo

Sponsor

GlaxoSmithKline